Brenzavvy (bexagliflozin) / TheracosBio  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brenzavvy (bexagliflozin) / TheracosBio
NCT02715258: Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Completed
3
210
Canada, US
Bexagliflozin, EGT0001442, Placebo
Theracos
Type 2 Diabetes Mellitus
04/17
04/17
NCT02836873 / 2016-002580-34: Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Completed
3
312
Europe, Japan, US
Bexagliflozin, EGT0001442, EGT0001474, Placebo
Theracos
Type 2 Diabetes Mellitus
01/18
01/18
NCT02558296 / 2015-001760-19: Bexagliflozin Efficacy and Safety Trial

Completed
3
1700
Europe, Canada, US, RoW
Bexagliflozin, EGT0001442, EGT0001474, Placebo
Theracos
Type 2 Diabetes Mellitus
08/18
10/19
NCT03115112 / 2017-000420-95: Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed
3
386
Europe, Japan, US, RoW
Bexagliflozin, EGT0001442, EGT0001474, Sitagliptin, Januvia, Placebo for sitagliptin, Placebo for bexagliflozin
Theracos
Type 2 Diabetes Mellitus
10/18
10/18
NCT03259789: Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed
3
351
Japan, US
Bexagliflozin tablets, 20 mg, EGT0001442, EGT0001474, Bexagliflozin tablets, placebo
Theracos
Type2 Diabetes Mellitus
01/19
01/19
NCT02769481 / 2016-002013-21: Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed
3
426
Europe, US
Bexagliflozin, EGT0001442, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
Theracos
Type 2 Diabetes Mellitus
06/19
06/19
NCT05159882: Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

Recruiting
3
390
RoW
THR-1442 and Dapagliflozin placebo, Dapagliflozin 10mg and THR1442 placebo
Newsoara Biopharma Co., Ltd.
T2DM
09/22
09/22
NCT03514641: An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Completed
2/3
673
US
Bexagliflozin, EGT0001442, Placebo
Theracos
Essential Hypertension
11/18
11/18

Download Options